A Study of the Transition From Cangrelor to Clopidogrel or Prasugrel in Patients With Coronary Artery Disease.
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2018
Price : $35 *
At a glance
- Drugs Cangrelor (Primary) ; Clopidogrel; Prasugrel
- Indications Coronary artery disease
- Focus Pharmacodynamics
- Sponsors Medicines Company
- 31 Aug 2018 Biomarkers information updated
- 26 Mar 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Jan 2014 as reported by ClinialTrials.gov